EKF Diagnostics Celebrates Success at MEDICA 2012
EKF Diagnostics Holdings plc
Avon House, 19 Stanwell Road,
Cardiff, United Kingdom
Press release date: December 4, 2012
Attendance statistics highlight interest in new point-of-care tools
Cardiff, UK - EKF Diagnostics' success at MEDICA 2012 has been highlighted by a list of impressive statistics. The worldwide manufacturer of point-of-care (POC) diagnostic tools attracted numerous visitors to find out more about the 10 key products displayed on its 100m▓ stand. Generating the greatest interest was the European launch of two new POC products: the Quo-Lab glycated haemoglobin (HbA1c) analyser for the affordable management of diabetes; and the STAT-Site(TM) M βHB strip-based analyser, for highly accurate near patient testing of ketosis.
Over 200 product demos and 66 customer meetings were given to delegates to demonstrate the qualities of EKF Diagnostics' newest POC solutions. The semi-automated, CE marked Quo-Lab analyser monitors HbA1c, which is increasingly used in the detection and management of diabetes, and provides a highly accurate, affordable and easy-to-use technology for GP surgeries, diabetes clinics and laboratories. The STAT-Site(TM) M βHB has been developed for the measurement of ▀-Hydroxybutyrate (βHB), the main ketone produced during ketosis, and provides a quantitative and accurate assessment of patients displaying symptoms of ketosis. This makes ketosis testing easier and more affordable in POC settings.
Nine free mini-seminars, attended by 121 delegates, outlined the benefits of using Quo-Lab and STAT Site(TM) M βHB, alongside the Lactate Scout+ for lactate measurement in obstetrics, and the Hemo-Control Manager for haemoglobin analysis and data management. A range of clinical chemistry reagents were also presented by EKF product specialists, including the ▀-Hydroxybutyrate (βHB) LiquiColor« Reagent System developed by EKF subsidiary, Stanbio Laboratory, which is relied on by 13 of the USA's top 25 diabetes and endocrinology hospitals for its rapid and reliable results.
According to Julian Baines, Group CEO, "The launch of our two new POC products for diabetes and ketosis testing at Medica this year was a tremendous success, which was reflected in the interest shown by the large number of attendees visiting our stand. We were delighted with the response to our seminar series. The seminars provided a great way to update customers Quo-Lab and STAT-Site M BHB and also brush up their knowledge on established EKF products."
For more information please visit www.ekfdiagnostics.com.
About EKF Diagnostics
EKF Diagnostics Holdings plc specialises in the development, production and worldwide distribution of point-of-care blood analysers for use in the detection and management of diabetes, anaemia, lactate and kidney related diseases.
EKF Diagnostics' expertise covers the entire in vitro diagnostics chain, from fermentation and enzyme production, to the manufacture of liquid reagents, the design and building of world-class diagnostic devices and the distribution of rapid test kits for infectious diseases and pregnancy. The EKF range of analysers are a trusted brand in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for the measurement of glucose, lactate, haemoglobin, haematocrit and HbA1c.
EKF Diagnostics products are sold in more than 100 countries around the globe. EKF Diagnostics' strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world's foremost authorities in medical diagnostics.
EKF Diagnostics Holdings plc
t: +44 (0)29 20 710570
Alto Marketing Limited
t: +44 (0)1489 557672